Fluralaner (Bravecto) for Canine Generalized Demodicosis: Field Study Evidence

Bottom line

• Fluralaner (Bravecto) achieves 98.0% mite-free rates in generalized canine demodicosis across both oral chewable and spot-on formulations in a 134-dog European multicenter field study — with both forms outperforming imidacloprid/moxidectin, which failed the 90% efficacy threshold at 87.5% mite-free.[1]
• A controlled laboratory study found that a single topical application of fluralaner spot-on eliminated Demodex sp. mites at 99.7% efficacy by Day 28, exceeding 99.9% by Day 56, and reaching 100% by Day 84 — compared to 9.8%, 45.4%, and 0% for topical imidacloprid/moxidectin given three times.[2]
• Fluralaner belongs to the isoxazoline class, which carries a label warning for neurologic adverse reactions (tremors, ataxia, seizures); use with particular caution in dogs with a prior seizure history.
• The oral (chewable) formulation of fluralaner is FDA-approved in the US for fleas and ticks (NADA 141-426); demodicosis use with the oral chew is off-label in the US, while the topical spot-on has EMA authorization that includes generalized demodicosis.

Drug facts

• Class: Isoxazoline ectoparasiticide
• Mechanism: Potent inhibitor of GABA-gated chloride channels and glutamate-gated chloride channels in invertebrates; high selectivity for arthropod receptors over mammalian receptors underlies the safety margin
• Route/interval: Oral chewable tablet or topical spot-on; a single administration is used for demodicosis (distinct from the every-12-weeks dosing interval for flea/tick prevention)
• Indication: Generalized canine demodicosis (off-label for US oral chewable formulation; EMA-authorized for the topical spot-on)
• Approval: FDA NADA 141-426 (US, oral/chewable, flea/tick); EMA authorization includes demodicosis for topical spot-on formulation
• Label contraindications: Use with caution in dogs with a history of seizures or neurologic disorders
• Label common AEs: Vomiting, decreased appetite, diarrhea, lethargy, hypersalivation; class-level warning for tremors, ataxia, and seizures

A specific patient on fluralaner for demodicosis?

Get an instant cited answer — no signup needed for your first question. Voyage Clinical Desk brings species-specific dose math, monitoring plans, and peer-reviewed evidence to the case in front of you.

Try Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=fluralaner-canine-generalized-demodicosis

What the evidence shows

Controlled laboratory comparison: spot-on formulations

Fourie et al. (2019, Parasites & Vectors (https://pubmed.ncbi.nlm.nih.gov/30683143/)) enrolled 16 client-owned dogs with naturally acquired generalized demodicosis in a randomized controlled laboratory study. Dogs were allocated to either a single topical application of fluralaner spot-on (Day 0 only) or three applications of topical imidacloprid/moxidectin on Days 0, 28, and 56 (weekly in severe cases). Mite burden was quantified from five deep skin scraping sites per dog at 28-day intervals over 12 weeks.

By Day 28, the fluralaner group achieved 99.7% miticidal efficacy; by Day 56, greater than 99.9%; and by Day 84, 100%. In contrast, the imidacloprid/moxidectin group reached only 9.8% efficacy at Day 28, 45.4% at Day 56, and 0% at Day 84, with statistically significant differences at all post-treatment time points (P < 0.01). The complete failure of efficacy in the imidacloprid/moxidectin group at Day 84, despite three or more treatments, underscores the pronounced pharmacokinetic advantage of fluralaner: a long tissue half-life (9.3 to 16.2 days following oral administration) sustains miticidal concentrations well beyond the initial treatment.

Multicenter European field study: oral and topical formulations compared

Petersen et al. (2020, Parasites & Vectors (https://pubmed.ncbi.nlm.nih.gov/32527282/)) conducted a larger randomized field assessment across veterinary clinics in five European countries, enrolling 134 dogs with naturally acquired generalized demodicosis (124 completers). Dogs were allocated 2:2:1 to fluralaner oral chewable (single dose), fluralaner spot-on (single dose), or topical imidacloprid/moxidectin per the label (three applications at 28-day intervals). The prespecified efficacy threshold was greater than 90% mite-free at Days 56 and 84.

Both fluralaner formulations met the threshold: 98.0% mite-free for oral and 98.0% for spot-on. The comparator did not: 87.5% mite-free overall (92.0% juvenile-onset, 81.8% adult-onset), falling below the threshold. Importantly, the fluralaner groups showed marked skin lesion reduction by Day 28, well ahead of full mite clearance, and no treatment-related adverse events were recorded.

The 2:2:1 design also provides a direct within-study comparison of oral and topical fluralaner: both achieved equivalent results, offering practical flexibility for cases where one route may be preferable.

Juvenile-onset vs. adult-onset demodicosis

The Petersen 2020 data stratified by age-of-onset show that both forms responded well across both subtypes: the oral fluralaner group achieved 96.0% mite-free for juvenile-onset and 100% for adult-onset; the spot-on group achieved 100% for juvenile-onset and 96.7% for adult-onset. These rates are notable for adult-onset generalized demodicosis, which is associated with underlying immunosuppression and has historically been considered more refractory.

Safety considerations and the isoxazoline class warning

Since 2018, the FDA has required a class-wide label warning for isoxazoline ectoparasiticides — including fluralaner — regarding the potential for neurologic adverse reactions (tremors, ataxia, seizures). The warning applies particularly to dogs with a history of seizures or neurologic disorders. Neither the Fourie 2019 nor the Petersen 2020 study reported treatment-related adverse events, and the fluralaner chewable field study (NADA 141-426 supporting data, n=294) confirmed a favorable safety profile. Nevertheless, the class warning should inform case selection; patients with underlying neurologic disease warrant discussion with the owner and heightened post-treatment monitoring.

How this fits clinical practice

Generalized canine demodicosis has historically been managed with amitraz dips, daily oral ivermectin-class drugs (off-label), or topical imidacloprid/moxidectin — all protocols that required weeks of daily or frequent administration and carried meaningful tolerability challenges. The two studies reviewed here establish a different pattern: a single administration of fluralaner, in either oral or topical form, consistently achieves and sustains miticidal efficacy well past the 84-day endpoint.

Clinically, the most relevant implication is simplification of the treatment schedule. A single dose replaces multi-week daily administration for most cases, which improves owner compliance and reduces the cumulative drug exposure that attends daily oral isoxazolines.

The equivalence of oral and topical formulations in the multicenter field study matters for case management: patients with compliance barriers to oral administration (e.g., severe vomiting, liver disease, behavioral challenges with pilling) can be offered the topical option without compromising efficacy expectations.

Adult-onset generalized demodicosis warrants investigation for underlying immunosuppression or systemic disease regardless of treatment chosen; fluralaner addresses the mite burden but does not modify the underlying cause if one exists.

Concomitant use with other ectoparasiticides and the full NADA label (NADA 141-426) should be reviewed before use in dogs with any seizure history. Monitoring for neurologic signs post-administration is prudent in higher-risk patients.

Voyage Clinical Desk

From clinical question to SOAP draft — cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=fluralaner-canine-generalized-demodicosis

References

1. Petersen I, Eppler A, Meyer L, Fourie JJ, Thomas E. A European field assessment of the efficacy of fluralaner (Bravecto) chewable and spot-on formulations for treatment of dogs with generalized demodicosis. Parasites & Vectors. 2020;13:304. https://pubmed.ncbi.nlm.nih.gov/32527282/
2. Fourie JJ, Meyer L, Thomas E. Efficacy of topically administered fluralaner or imidacloprid/moxidectin on dogs with generalised demodicosis. Parasites & Vectors. 2019;12(1):59. https://pubmed.ncbi.nlm.nih.gov/30683143/

Changelog

• 2026-06-08: First published.

Related reads

• Oclacitinib (Apoquel) for Canine Atopic Dermatitis: JAK Inhibition and Clinical Evidence
• Grapiprant (Galliprant) for Canine Osteoarthritis Pain: EP4 Antagonism and Clinical Evidence
• Robenacoxib Dogs Cats Pain